Compass Pathways is trading at $13.12, down 4.58%, alongside a 2.04% decline in the biotechnology sector. - Broader markets are lower as higher Treasury yields, inflation concerns, and firmer crude oil pressure growth-oriented stocks. - No clearly reported negative company-specific announcement was identified for September 24, 2026; recent coverage focuses on COMP360’s rolling FDA review and potential 2027 launch. - The move is best characterized as sector- and macro-driven rather than company-specific.